Proctor suggested that the effective agent in the first trial was a pharmacologically-active breakdown product of NXY-059, MNP, and that stabilization of NYX-059 to prevent such breakdown was responsible for the failure of the second trial.
Proctor suggested that the effective agent in the first trial was a pharmacologically-active breakdown product of NXY-059, MNP or "methylnitrosopropane", to which he also holds patent claims. He further proposed that stabilization of Cerovive to prevent such breakdown was responsible for the failure of the second trial.